Small Pharma Announces Significant Developments In Intellectual Property Portfolio
5 new patent grants with 3 expected upcoming patent grants in May.
Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
Patients who achieved remission within three months sustained remission to six months.
Small Pharma announces further positive data from SPL026 Phase IIa trial in Major Depressive Disorder strengthening topline efficacy results
Statistically significant improvement in anxiety symptoms offers potential in indications beyond depression.
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
The Phase I study will compare IV and IM routes of SPL028 administration.
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
Two new patents approved for issue bringing total to 16 granted patents.
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
Positive top-line results from Phase IIa trial of SPL026 in MDD with new trials underway.
Small Pharma reports positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder
Primary endpoint met. SPL026 demonstrates rapid and durable response.
First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
Study will compare the profile of intramuscular versus intravenous SPL026 administration.
Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
Last patient last visit complete in SPL026 Phase IIa clinical trial, plus new European patent…
First patient dosed in Small Pharma’s Drug Interaction study
Open-label study will assess the interaction between SSRI antidepressants and SPL026.